Alterity Therapeutics (NASDAQ:ATHE) Trading 2.1% Higher – What’s Next?

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE)’s share price traded up 2.1% on Thursday . The company traded as high as $4.15 and last traded at $3.92. 90,255 shares were traded during mid-day trading, a decline of 37% from the average session volume of 144,307 shares. The stock had previously closed at $3.84.

Alterity Therapeutics Price Performance

The company’s 50 day simple moving average is $4.15 and its 200-day simple moving average is $3.71.

Hedge Funds Weigh In On Alterity Therapeutics

A number of large investors have recently bought and sold shares of ATHE. BNP Paribas Financial Markets purchased a new stake in Alterity Therapeutics in the fourth quarter worth $29,000. Point72 Asset Management L.P. purchased a new position in Alterity Therapeutics in the 4th quarter worth about $108,000. Finally, HB Wealth Management LLC lifted its holdings in Alterity Therapeutics by 17.6% during the 1st quarter. HB Wealth Management LLC now owns 37,483 shares of the company’s stock valued at $129,000 after buying an additional 5,600 shares in the last quarter. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.